Impact BioMedical Secures Canadian Patent for Inflammatory Relief
Impact BioMedical Celebrates a Milestone in Patent Issuance
Impact BioMedical Inc. (NYSE: IBO) is excited to share a significant achievement regarding its innovative Linebacker™ technology platform. Recently, the Canadian Intellectual Property Office granted Canadian Patent #3,024,728 for Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders. This patent encompasses groundbreaking enhanced phenolic compounds and their pharmaceutical compositions designed to treat various inflammatory diseases.
Understanding the Linebacker™ Technology
The Linebacker™ technology stands as a collection of small molecule compounds strategically developed to target key pathways involved in the inflammatory process. The objective is to potentially reduce inflammation while offering symptomatic relief. A crucial aspect of this platform is its aim to lessen the side effects often linked to conventional anti-inflammatory medications.
Wider Implications of the Patent
The newly awarded patent describes a methodology utilizing a formulation from the Linebacker™ range of novel compounds. This formulation shows promise in inhibiting inflammatory responses, potentially benefiting conditions like arthritis, asthma, and inflammatory bowel disease. This achievement represents the first issuance of a Linebacker™ patent in Canada, underlining Impact BioMedical’s dedication to innovating unique technologies that address pressing healthcare needs.
Market Perspective and Future Aspirations
Frank D. Heuszel, the CEO of Impact BioMedical, shared insights on the expanding market for inflammatory disease treatments, estimated at around $7 billion in 2022. Heuszel emphasized that this patent issuance is a pivotal step in enhancing the company's intellectual property portfolio and showcases the transformative potential of their Linebacker™ technology, both commercially and therapeutically.
About Impact BioMedical Inc.
Impact BioMedical Inc. focuses on identifying, validating, and patenting pioneering science and technologies that lead to groundbreaking solutions in human healthcare and wellness. Once innovations are developed, the company engages in licensing, co-development, and establishing partnerships to bring these solutions to the market efficiently. For more detailed information about the company, you can visit their website.
Exploring Linebacker™ Technology Further
The Linebacker™ platform is centered on small molecule electrophilically enhanced polyphenols. These compounds hold potential applications across various fields, including oncology for solid tumors, inflammatory disorders, and neurology. Derived from natural sources such as nuts, vegetables, and berries, these polyphenols, specifically myricetin, have been modified to enhance their properties.
Collaboration for Development
Impact BioMedical has licensed its Linebacker™ -1 and Linebacker™ -2 compounds to ProPhase Laboratories for their development and commercialization. This partnership reflects the company’s strategic approach to advancing their technologies and ensuring they reach those who need them the most.
Contact and Investor Relations
The company maintains an open line for communication regarding inquiries. Interested parties can reach out via email for further information.
Frequently Asked Questions
What is the significance of the Canadian patent for Impact BioMedical?
The Canadian patent allows Impact BioMedical to protect its innovative Linebacker™ technology and enhances its intellectual property portfolio, crucial for advancing treatment options for inflammatory diseases.
What conditions does the Linebacker™ technology target?
The Linebacker™ technology is focused on targeting various inflammatory conditions such as arthritis, asthma, and inflammatory bowel disease.
Who is the CEO of Impact BioMedical?
Frank D. Heuszel serves as the CEO of Impact BioMedical, guiding the company’s strategic vision and market developments.
What are the future applications of Linebacker™ technology?
Future applications of Linebacker™ technology are anticipated in oncology, inflammatory disorders, and neurology, expanding its impact on healthcare.
How does Impact BioMedical work with partners?
Impact BioMedical collaborates through licensing, co-development, and joint ventures to bring its innovative healthcare solutions to the market effectively.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Orion Group's Resilience in the Face of Hurricane Milton's Impact
- Volvo Group's Vision for a Sustainable Future at CES 2025
- SELLAS Life Sciences Achieves FDA Designation for Cancer Drug
- Kerry Cooper Stepping Up as New Chair for PG&E Corporation
- Blueberry AI Unveils Kiwi Engine for Enhanced 3D Asset Management
- Raymond James Adjusts Price Target for Applied Materials Stock
- Elliott Investment Management Introduces Podcast for Southwest Airlines
- Diamond Hill Introduces New Core Plus Bond Strategy for Growth
- Insight into Saudi Arabia's Recent Stock Market Performance
- UBS Raises S&P 500 Projection for 2025 to 6400 Amid Optimism
Recent Articles
- Sound Growth Partners Strengthens Portfolio with Stueve
- Global Net Lease to Share Q3 2024 Financial Performance Soon
- WeRide Introduces GXR: The Revolutionary Robotaxi Experience
- Karolinska Development AB Invites Shareholders to EGM
- Excelsior Energy Partners with Proximal for AI-Driven Solutions
- Sycamore and Quik! Join Forces to Elevate Wealth Management
- North Shore Animal League America Provides Lifesaving Support
- Investors Strongly Encouraged to Join Edwards Lifesciences Class Action
- Diversity Champions: Celebrating Latino Board Leadership in 2024
- IFS and Sovos Partner to Enhance Global Tax Compliance Strategies
- Moss Adams Unveils Plans for 2024 Executive Health Care Event
- Eggland's Best Celebrated as Best Egg in Prestigious Awards
- Citi Raises Bull Case Oil Price Forecasts Amid Market Uncertainty
- Surge in Trump Media Shares Signals Investor Optimism Ahead of Election
- Exploring Two Dividend Powerhouses Worth Holding Long-term
- Important Update for GitLab Inc. Shareholders Amid Lawsuit
- Lessons from Annaly Capital Management on Dividend Investment
- Ardelyx, Inc. Faces Class Action Lawsuit Amid Allegations
- Is Nvidia Still the Top AI Investment? Explore These Alternatives
- Federal Reserve's Interest Rate Strategy Sparks Discussions
- Exploring Palantir Technologies: A Deep Dive into AI Potential
- Important Class Action Notice for STMicroelectronics Investors
- Terran Orbital Corporation Faces Class Action Lawsuit
- Outset Medical Faces Class Action Lawsuit Over Alleged Fraud
- Bumble Inc. Faces Class Action Lawsuit Over Stock Losses
- DexCom, Inc. Faces Legal Action Over Alleged Securities Violations
- Legal Action Against Extreme Networks: Investors Take Stand
- HighPeak Energy Prepares for Q3 2024 Earnings with Call
- Agenus Inc. Lawsuit Update: Shareholder Actions Explained
- Investors Alert: New Fortress Energy Faces Legal Challenges
- UnitedHealth Group's Q3 2024 Financial Performance Explored
- Iris Energy Class Action Alert: Key Details for Investors
- Endava Investors Reminded of Class Action Lawsuit Deadline
- Exciting Addition to MyCardiologist as Dr. Koshy Joins Team
- Seeking Justice for Sage Therapeutics Investors: Join the Class Action
- MKBHD's Bold Promise Regarding Tesla's Robotaxi Future
- Understanding the Implications of Sprinklr, Inc.'s Lawsuit for Investors
- Investors Take Note: Methode Electronics Faces Securities Lawsuit
- Starbucks Faces Securities Lawsuit: Key Details for Investors
- Investors Alerted: Class Action Lawsuit Against Verve Therapeutics
- Legal Action for Elanco Animal Health Investors: What You Need to Know
- Class Action Lawsuit Against Orthofix Medical Inc. Details
- Romania's Path to Interest Rate Cuts Affected by Fiscal Strategy
- Fed's Interest Rate Strategy Sparks Insights from Morgan Stanley
- Coty Faces Sales Slowdown Amidst Beauty Market Challenges
- Bellway Projects Strong Home Construction Growth for 2025
- Market Dynamics: US Dollar and Stocks Continue Their Ascent
- Investors Shift Towards Growth: A Bullish Outlook on Stocks
- Transforming Industries: The Rise of Industrial Drones
- Exploring WisdomTree's Investment Strategies and Fund Performance